CD69 and B-cell chronic lymphocytic leukemia: To confirm the potential value of CD69 as a new biomarker of bendamustine response in CLL, we analyzed whether its predictive significance was independent from the main clinical and biological characteristics of CLL cases included in the study (n = 77).